S&P Futures
3,656.50 +2.25 (+0.06%) Dow Futures
29,274.00 -11.00 (-0.04%) Nasdaq Futures
11,230.00 +1.75 (+0.02%) Russell 2000 Futures
1,683.20 +1.10 (+0.07%) Crude Oil
81.34 +0.11 (+0.14%) Gold
1,671.80 +3.20 (+0.19%)
TCR2 Therapeutics Inc. (TCRR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7900 |
| Open | 1.7800 |
| Bid | 1.7100 x 1000 |
| Ask | 1.8900 x 1000 |
| Day's Range | 1.7200 - 1.8600 |
| 52 Week Range | 1.6900 - 8.8200 |
| Volume | |
| Avg. Volume | 262,706 |
| Market Cap | 66.403M |
| Beta (5Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8050 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.78 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TCRR
Related Research
- TCR2 Therapeutics Inc.Technical Assessment: Neutral in the Intermediate-TermInterest rates across the entire curve went somewhat parabolic in August. The U.S. Dollar Index continued its very steep ascent. The Federal Reserve is maintaining its hawkish stance based on its latest fed funds targets. As well, the Fed "finally" is getting its quantitative tightening (QT) in gear, which pulls liquidity out of the marketplace. Oh, and stock investors have been losing massive amounts of money. One might believe the economy is falling off a cliff. At least gasoline prices have crashed.RatingFair ValueEconomic Moat2 days agoArgus Research
- Benzinga
TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma
TCR2 Therapeutics Inc (NASDAQ: TCRR) has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. Gavo-cel demonstrated a disease control rate (DCR) of 77%. 28 of the 30 (93%) patients evaluable for efficacy experienced tumor regression of their target lesions, ranging in magnitude from 4% to 80%. Eight patients experienced target lesion regression greater than 30%, six of whom achieved a partial response (PR). One patient with ch
- GlobeNewswire
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underw
- GlobeNewswire
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T. In order to parti
- Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY StudyGlobeNewswire
- European Medicines Agency Qualifies Unlearn’s AI-powered Method for Running Smaller, Faster Clinical TrialsBusiness Wire
